21st Century Oncology, Inc -- Moody's upgrades 21st Century Oncology's CFR to B3; outlook stable

New York, February 25, 2015 -- Moody's Investors Service upgraded 21st Century Oncology, Inc.'s ("21st Century") Corporate Family Rating and Probability of Default Rating to B3 and B3-PD, respectively. Concurrently, the ratings on the company's $100 million revolving credit facility and $90 million term loan are upgraded to Ba3 from B1, the rating on the company's existing $350 million 8.875% second lien notes is upgraded to B2 from Caa2, and the rating on the $380 million 9.875% subordinated notes is upgraded to Caa2 from Caa3. The company's speculative grade liquidity rating ("SGL") is upgraded to SGL-2 from SGL-3. The rating outlook is stable. This concludes the review of 21st Century's ratings that was initiated on October 1, 2014.

Vollständigen Artikel bei Moodys lesen